Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.

Blood
C SchmaltzM R van den Brink

Abstract

In allogeneic bone marrow transplantation (BMT) donor T cells are primarily responsible for antihost activity, resulting in graft-versus-host disease (GVHD), and for antileukemia activity, resulting in the graft-versus-leukemia (GVL) effect. The relative contributions of the Fas ligand (FasL) and perforin cytotoxic pathways in GVHD and GVL activity were studied by using FasL-defective or perforin-deficient donor T cells in murine parent --> F1 models for allogeneic bone marrow transplantation. It was found that FasL-defective B6.gld donor T cells display diminished GVHD activity but have intact GVL activity. In contrast, perforin-deficient B6.pfp(-/-) donor T cells have intact GVHD activity but display diminished GVL activity. Splenic T cells from recipients of B6.gld or B6.pfp(-/-) T cells had identical proliferative and cytokine responses to host antigens; however, splenic T cells from recipients of B6.pfp(-/-) T cells had no cytolytic activity against leukemia cells in a cytotoxicity assay. In experiments with selected CD4(+) or CD8(+) donor T cells, the FasL pathway was important for GVHD activity by both CD4(+) and CD8(+) T cells, whereas the perforin pathway was required for CD8-mediated GVL activity. These data demonstra...Continue Reading

References

Jan 1, 1990·European Journal of Immunology·P StrackS T Ju
Mar 7, 1991·The New England Journal of Medicine·J L Ferrara, H J Deeg
Apr 7, 1995·Cell·G Berke
Jan 1, 1995·Journal of Molecular and Cellular Cardiology·T Brand, M D Schneider
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·B LowinJ Tschopp
Nov 1, 1993·Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy·J H FalkenburgR Willemze
Nov 1, 1996·The Journal of Experimental Medicine·M E van den BroekH Hengartner
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·M B BakerR B Levy
Feb 7, 1997·Cell·S Nagata
Aug 1, 1997·Tissue Antigens·P J MartinJ A Hansen
Aug 27, 1997·Transplantation·W KrengerJ L Ferrara
Jan 14, 1998·Nature Medicine·A Strasser, L O'Connor
Jan 14, 1998·Nature Medicine·M TanakaS Nagata
Apr 10, 1999·The Journal of Biological Chemistry·M R van den BrinkS J Burakoff
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·D C HuangA Strasser
Apr 5, 2000·The Journal of Experimental Medicine·A M HohlbaumA Marshak-Rothstein
Oct 18, 2000·The Journal of Experimental Medicine·S Roy, D W Nicholson
Jul 1, 1957·British Journal of Haematology·D W BARNES, J F LOUTIT

❮ Previous
Next ❯

Citations

Sep 3, 2008·Bone Marrow Transplantation·W R DrobyskiW Grossman
Dec 17, 2008·Bone Marrow Transplantation·B KircherD Nachbaur
Jul 24, 2008·Bone Marrow Transplantation·L M BallUNKNOWN EBMT Paediatric Working Party
Sep 1, 2009·Bone Marrow Transplantation·A MeguroK Ozawa
Jan 22, 2013·Nature Reviews. Drug Discovery·Michael CroftCarl F Ware
Apr 18, 2007·Nature Reviews. Immunology·Warren D Shlomchik
May 11, 2002·Nature Reviews. Immunology·Marcel R M van den Brink, Steven J Burakoff
Jan 19, 2002·Seminars in Hematology·Takanori Teshima, James L M Ferrara
Jul 14, 2004·The Journal of Experimental Medicine·Stephanie J MuriglanMarcel R M Van Den Brink
Oct 18, 2001·Current Opinion in Hematology·K S Peggs, S Mackinnon
Oct 24, 2002·Current Opinion in Hematology·Ernst Holler
Mar 16, 2011·Transplantation·Nicolas RuffinAnne M Dickinson
Feb 28, 2002·Annual Review of Immunology·John H Russell, Timothy J Ley
Nov 30, 2006·Annual Review of Immunology·Lisbeth A WelniakWilliam J Murphy
Jul 10, 2010·Journal of Biomedicine & Biotechnology·David LaurinJoël Plumas
Oct 15, 2005·The Journal of Clinical Investigation·Edward S MorrisGeoffrey R Hill
Dec 4, 2009·The Journal of Clinical Investigation·Il-Kang NaMarcel R M van den Brink
Nov 13, 2009·The Journal of Clinical Investigation·Javier O ValenzuelaAmer A Beg
Jul 23, 2005·Blood·Theis H TerweyMarcel R M van den Brink
Sep 6, 2007·Orphanet Journal of Rare Diseases·David A Jacobsohn, Georgia B Vogelsang
Aug 3, 2002·Leukemia & Lymphoma·A B T FassasG Tricot
Dec 3, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Joanne E DavisDavid S Ritchie
Apr 30, 2013·Biochemical and Biophysical Research Communications·Eun-Kee SongChang-Yeol Yim
Sep 18, 2012·Transplant Immunology·Eun-Kee SongChang-Yeol Yim
Jul 20, 2011·Experimental Hematology·Ji-Young LimChang-Ki Min

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.